Our Commercial and Development Pipeline is Focused on Serving the
Unmet Medical Needs of Patients Across a Range of Therapeutic Areas
Therapeutic Development Pipeline
1. Sales of Macrilen® (macimorelin) are temporarily discontinued in the United States commercial market for the diagnosis of adult growth hormone deficiency ("AGHD"), until anticipated re-launch with an alternate commercialization partner. Aeterna has an ongoing effort to identify strategic development and commercialization partner.